BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res 2014;31:2643-54. [PMID: 24789450 DOI: 10.1007/s11095-014-1361-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Ghoneim RH, Thabit AK, Lashkar MO, Ali AS. Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation. Ital J Pediatr 2021;47:167. [PMID: 34362436 DOI: 10.1186/s13052-021-01114-4] [Reference Citation Analysis]
2 Crcek M, Zdovc J, Kerec Kos M. A review of population pharmacokinetic models of gentamicin in paediatric patients. J Clin Pharm Ther 2019;44:659-74. [PMID: 31102287 DOI: 10.1111/jcpt.12850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bhongsatiern J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin CM. Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance? J Clin Pharmacol 2016;56:528-40. [PMID: 26412385 DOI: 10.1002/jcph.650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Danhof M. Systems pharmacology - Towards the modeling of network interactions. Eur J Pharm Sci. 2016;94:4-14. [PMID: 27131606 DOI: 10.1016/j.ejps.2016.04.027] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 12.8] [Reference Citation Analysis]
5 Llanos-Paez CC, Hennig S, Staatz CE. Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. J Antimicrob Chemother 2017;72:639-67. [PMID: 28062683 DOI: 10.1093/jac/dkw461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. J Antimicrob Chemother 2019;74:2128-38. [PMID: 31049551 DOI: 10.1093/jac/dkz158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
7 Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ. Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. Pharm Res 2019;36:112. [PMID: 31147853 DOI: 10.1007/s11095-019-2651-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Völler S, Flint RB, Simons SHP, Knibbe CAJ. Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II". Clin Pharmacokinet 2021;60:677-9. [PMID: 33713305 DOI: 10.1007/s40262-021-00993-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 D'Agate S, Musuamba FT, Jacqz-Aigrain E, Della Pasqua O. Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis. Front Pharmacol 2021;12:624662. [PMID: 33762945 DOI: 10.3389/fphar.2021.624662] [Reference Citation Analysis]
10 An SH, Lee EM, Kim JY, Gwak HS. Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation. Eur J Hosp Pharm 2020;27:e25-9. [PMID: 32296501 DOI: 10.1136/ejhpharm-2018-001720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Tasa T, Metsvaht T, Kalamees R, Vilo J, Lutsar I. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates. Therapeutic Drug Monitoring 2017;39:604-13. [DOI: 10.1097/ftd.0000000000000456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
12 Salem F, Johnson TN, Hodgkinson ABJ, Ogungbenro K, Rostami-Hodjegan A. Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine Bias. J Clin Pharmacol 2021;61:159-71. [PMID: 32885464 DOI: 10.1002/jcph.1725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Allegaert K, Flint R, Smits A. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. Expert Opin Drug Metab Toxicol 2019;15:735-49. [PMID: 31402708 DOI: 10.1080/17425255.2019.1655540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
14 van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental Changes in Pharmacokinetics and Pharmacodynamics. The Journal of Clinical Pharmacology 2018;58:S10-25. [DOI: 10.1002/jcph.1284] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 16.0] [Reference Citation Analysis]
15 Ayuso M, Buyssens L, Stroe M, Valenzuela A, Allegaert K, Smits A, Annaert P, Mulder A, Carpentier S, Van Ginneken C, Van Cruchten S. The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development. Pharmaceutics 2020;13:44. [PMID: 33396805 DOI: 10.3390/pharmaceutics13010044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zeilmaker GA, Pokorna P, Mian P, Wildschut ED, Knibbe CAJ, Krekels EHJ, Allegaert K, Tibboel D. Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. Expert Opin Drug Metab Toxicol 2018;14:417-28. [PMID: 29623729 DOI: 10.1080/17425255.2018.1461836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
17 Le J, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. J Clin Pharmacol 2018;58 Suppl 10:S108-22. [PMID: 30248202 DOI: 10.1002/jcph.1128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
18 Allegaert K, Smits A, Simons S, Van den Anker J. Perspectives in Neonatal Pharmacology: Drug Discovery, Knowledge Integration and Structured Prioritization. Curr Pharm Des 2018;24:4839-41. [PMID: 30963966 DOI: 10.2174/138161282441190320125910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Magliocco G, Rodieux F, Desmeules J, Samer CF, Daali Y. Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling. Pediatr Res 2020;87:441-9. [DOI: 10.1038/s41390-019-0609-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Pacifici GM, Allegaert K. Clinical pharmacokinetics of amoxicillin in neonates. Journal of Chemotherapy 2017;29:57-9. [DOI: 10.1179/1973947815y.0000000064] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Janssen EJ, Välitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother 2016;60:1013-21. [PMID: 26643337 DOI: 10.1128/AAC.01968-15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 6.1] [Reference Citation Analysis]
22 Liu X, Smits A, Wang Y, Renard M, Wead S, Kagan RJ, Healy DP, De Cock P, Allegaert K, Sherwin CM. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Therapeutic Drug Monitoring 2019;41:44-52. [DOI: 10.1097/ftd.0000000000000568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci 2017;109S:S22-6. [PMID: 28502674 DOI: 10.1016/j.ejps.2017.05.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
24 Parker SL, Abdul-Aziz MH, Roberts JA. The role of antibiotic pharmacokinetic studies performed post-licensing. Int J Antimicrob Agents 2020;56:106165. [PMID: 32941948 DOI: 10.1016/j.ijantimicag.2020.106165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Bijleveld YA, van den Heuvel ME, Hodiamont CJ, Mathôt RA, de Haan TR. Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria. Antimicrob Agents Chemother 2017;61:e01304-16. [PMID: 27795373 DOI: 10.1128/AAC.01304-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wu Y, Völler S, Flint RB, Simons SHP, Allegaert K, Fellman V, Knibbe CAJ. Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study. Clin Pharmacokinet 2021. [PMID: 34773609 DOI: 10.1007/s40262-021-01076-0] [Reference Citation Analysis]
27 Chung E, Sen J, Patel P, Seto W. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. Clin Pharmacokinet 2021;60:985-1001. [PMID: 34002357 DOI: 10.1007/s40262-021-01027-9] [Reference Citation Analysis]
28 Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 2016;56:909-35. [PMID: 26766774 DOI: 10.1002/jcph.705] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
29 Bloomfield C, Staatz CE, Unwin S, Hennig S. Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients. Antimicrob Agents Chemother 2016;60:3407-14. [PMID: 27001806 DOI: 10.1128/AAC.02654-15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
30 Rubino CM, Polak M, Schröpf S, Münch HG, Smits A, Cossey V, Tomasik T, Kwinta P, Snariene R, Liubsys A, Gardovska D, Hornik CD, Bosheva M, Ruehle C, Litherland K, Hamed K. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients. Pediatr Infect Dis J 2021;40:997-1003. [PMID: 34533489 DOI: 10.1097/INF.0000000000003296] [Reference Citation Analysis]
31 An G. The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants. Curr Pharmacol Rep 2020;6:260-6. [PMID: 33767946 DOI: 10.1007/s40495-020-00234-5] [Reference Citation Analysis]
32 Hartman SJF, Orriëns LB, Zwaag SM, Poel T, de Hoop M, de Wildt SN. External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. Paediatr Drugs 2020;22:433-44. [PMID: 32507958 DOI: 10.1007/s40272-020-00400-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chapron BD, Chapron A, Leeder JS. Recent advances in the ontogeny of drug disposition. Br J Clin Pharmacol 2021. [PMID: 33733546 DOI: 10.1111/bcp.14821] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Dhont E, Van Der Heggen T, De Jaeger A, Vande Walle J, De Paepe P, De Cock PA. Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients? Pediatr Nephrol 2020;35:25-39. [DOI: 10.1007/s00467-018-4120-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
35 Mooij MG, Nies AT, Knibbe CA, Schaeffeler E, Tibboel D, Schwab M, de Wildt SN. Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet 2016;55:507-24. [PMID: 26410689 DOI: 10.1007/s40262-015-0328-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
36 Calvier EAM, Krekels EHJ, Yu H, Välitalo PAJ, Johnson TN, Rostami-Hodjegan A, Tibboel D, van der Graaf PH, Danhof M, Knibbe CAJ. Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT Pharmacometrics Syst Pharmacol 2018;7:175-85. [PMID: 29399979 DOI: 10.1002/psp4.12273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
37 Smits A, Annaert P, Cavallaro G, De Cock PAJG, de Wildt SN, Kindblom JM, Lagler FB, Moreno C, Pokorna P, Schreuder MF, Standing JF, Turner MA, Vitiello B, Zhao W, Weingberg AM, Willmann R, van den Anker J, Allegaert K. Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. Br J Clin Pharmacol 2021. [PMID: 34180088 DOI: 10.1111/bcp.14958] [Reference Citation Analysis]
38 Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine. Antibiotics (Basel) 2021;10:1182. [PMID: 34680763 DOI: 10.3390/antibiotics10101182] [Reference Citation Analysis]
39 Alsultan A, Abouelkheir M, Elsharawy Y, Alkoraishi A, Osman R, Neely MN, Mansy W, Algahtani S. Optimizing Gentamicin Dosing in Pediatrics Using Monte Carlo Simulations. Pediatric Infectious Disease Journal 2019;38:390-5. [DOI: 10.1097/inf.0000000000002120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
40 Allegaert K, Simons SHP, Tibboel D, Krekels EH, Knibbe CA, van den Anker JN. Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. Eur J Pharm Sci 2017;109S:S27-31. [PMID: 28506866 DOI: 10.1016/j.ejps.2017.05.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
41 Cristea S, Krekels EHJ, Allegaert K, De Paepe P, de Jaeger A, De Cock P, Knibbe CAJ. Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. AAPS J 2021;23:65. [PMID: 33948771 DOI: 10.1208/s12248-021-00595-9] [Reference Citation Analysis]
42 van den Anker J. Paediatric extrapolation: the panacea for paediatric drug development? Br J Clin Pharmacol 2019;85:672-4. [PMID: 30536691 DOI: 10.1111/bcp.13836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Smits A, De Cock P, Vermeulen A, Allegaert K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol 2019;15:25-34. [PMID: 30554542 DOI: 10.1080/17425255.2019.1558205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
44 Smit C, Goulooze SC, Brüggemann RJM, Sherwin CM, Knibbe CAJ. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. AAPS J 2021;23:53. [PMID: 33839974 DOI: 10.1208/s12248-021-00577-x] [Reference Citation Analysis]
45 Krekels EH, Tibboel D, Knibbe CA. Pediatric pharmacology: current efforts and future goals to improve clinical practice. Expert Opin Drug Metab Toxicol 2015;11:1679-82. [PMID: 26166262 DOI: 10.1517/17425255.2015.1065815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
46 Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol 2016;12:367-75. [PMID: 26817821 DOI: 10.1517/17425255.2016.1147559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
47 Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit 2015;37:756-65. [PMID: 26562817 DOI: 10.1097/FTD.0000000000000216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
48 Dersch-mills D, Akierman A, Alshaikh B, Sundaram A, Yusuf K. Performance of a dosage individualization table for extended interval gentamicin in neonates beyond the first week of life. The Journal of Maternal-Fetal & Neonatal Medicine 2015;29:1451-6. [DOI: 10.3109/14767058.2015.1051021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Wang H, Sherwin C, Gobburu JVS, Ivaturi V. Population Pharmacokinetic Modeling of Gentamicin in Pediatrics. J Clin Pharmacol 2019;59:1584-96. [PMID: 31286535 DOI: 10.1002/jcph.1479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Cantey JB. Optimizing the Use of Antibacterial Agents in the Neonatal Period. Paediatr Drugs 2016;18:109-22. [PMID: 26748790 DOI: 10.1007/s40272-015-0161-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
51 Cristea S, Krekels EHJ, Allegaert K, Knibbe CAJ. The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties. Clin Pharmacokinet 2020;59:1291-301. [PMID: 32314184 DOI: 10.1007/s40262-020-00890-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]